ArticleEuropean heart journal. Cardiovascular pharmacotherapy2020
Might renin-angiotensin system blockers play a role in the COVID-19 pandemic?
Article in European heart journal. Cardiovascular pharmacotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Systematic review of the role of renin-angiotensin system inhibitors in late studies on Covid-19: A new challenge overcome?International journal of cardiology · 2020Pooled it
- Recommendations for Cardiovascular Prevention During the Sars-Cov-2 Pandemic: An Executive Document by the Board of the Italian Society of Cardiovascular Prevention.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2020Guideline
- Long-term oral ACEI/ARB therapy is associated with disease severity in elderly COVID-19 omicron BA.2 patients with hypertension.BMC infectious diseases · 2023Article
- Cardiovascular risk and the COVID-19 pandemic: A retrospective observational study in a population of healthcare professionals.Nutrition, metabolism, and cardiovascular diseases : NMCD · 2023Observational
- Olmesartan alleviates SARS-CoV-2 envelope protein induced renal fibrosis by regulating HMGB1 release and autophagic degradation of TGF-β1.Frontiers in pharmacology · 2023Article
- Angiotensin II Type I Receptor (AT1R): The Gate towards COVID-19-Associated Diseases.Molecules (Basel, Switzerland) · 2022Review
- The expression level of angiotensin-converting enzyme 2 determines the severity of COVID-19: lung and heart tissue as targets.Journal of biomolecular structure & dynamics · 2021Review
- The Renin-Angiotensin System, Hypertension, and SARS-CoV-2 Infection: a Review.Current hypertension reports · 2021Review
- A randomized trial supports the recommendation to continue treatment with ACEi or ARBs during hospitalization for COVID-19.European heart journal · 2021Article
- A Contemporary View of Natriuretic Peptides in the SARS-CoV-2 Era.Frontiers in physiology · 2021Review
- Observational
- Hypertension and renin-angiotensin system blockers are not associated with expression of angiotensin-converting enzyme 2 (ACE2) in the kidney.European heart journal · 2020Article
- COVID-19 and renin-angiotensin system inhibition: role of angiotensin converting enzyme 2 (ACE2) - Is there any scientific evidence for controversy?Journal of internal medicine · 2020Review
- Rationale and design of the PRAETORIAN-COVID trial: A double-blind, placebo-controlled randomized clinical trial with valsartan for PRevention of Acute rEspiraTORy dIstress syndrome in hospitAlized patieNts with SARS-COV-2 Infection Disease.American heart journal · 2020Article
- Two important controversial risk factors in SARS-CoV-2 infection: Obesity and smoking.Environmental toxicology and pharmacology · 2020Review
- Sacubitril/Valsartan: Potential Impact of ARNi "Beyond the Wall" of ACE2 on Treatment and Prognosis of Heart Failure Patients With Coronavirus Disease-19.Frontiers in cardiovascular medicine · 2020Article
- ACEIs and ARBs and Their Correlation with COVID-19: A Review.Infection and drug resistance · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since December 2019, a new coronavirus, named SARS-CoV-2, has spread globally, affecting >200 000 people worldwide with the so-called COVID-19 disease. The scientific community is actively and constantly working to identify the mechanisms involved in the diffusion of this virus and the pathogenesis of the infection, with its most frequent and severe complication, namely interstitial pneumonia. To date, SARS-CoV-2 is known to enter the host cells via the angiotensin-converting enzyme 2 protein. For this reason, the hypothesis that drugs capable of increasing the expression of this protein may have a role in the spread of the virus and in the symptomatology of affected patients has taken hold. The purpose of this Editorial is to briefly show the evidence currently available in this regard and to provide ideas for future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.